BellBrook

Transcreener ADP2 FI Assay

CHF 0.00
In stock
BBL-3013-A200 assaysCHF 532.00
BBL-3013-1K1000 assaysCHF 1'011.00
BBL-3013-10K10000 assaysCHF 5'152.00
BBL-3013-100K10 x 10000 assaysINQ
More Information
Product Details
Product Type Kit
Properties
Application Set Compound Screening
Crossreactivity All
Quantity

200 assays/96wells (BBL-3013-A)

1000 assays/384wells (BBL-3013-1K)

10000 assays/384wells (BBL-3013-10K)

Note: The exact number of assays depends on enzyme reaction conditions.

Sensitivity Excellent data quality (Z’ ≥ 0.7) at low substrate conversion (typically 10%).
Range Accommodates ATP concentrations ranging from 0.1 μM to 1,000 μM.
Detection Type Fluorescence intensity
Kit Contains

ADP2 Antibody-IRDye® QC-1, ADP Alexa Fluor®594 Tracer, Stop & Detect Buffer B, 10X, ATP, ADP

Note:  The plates are not included, please see manual for material not provided but necessary for assay.

Other Product Data

Click here for Complete Information from the Original Manufacturer
Our product description may differ slightly from the original manufacturers product datasheet.


Assay Features

Easy-to-Use (mix-and-read method).Simple homogenous biochemical assay. Direct detection of ADP eliminates laborious coupling steps. Non-radioactive, safe assay method. HTS Compatible with 96, 384, and 1536-well plates. Sensitive, robust detection of ADP. This means up to 10X less enzyme, a significant cost reduction on large screens.

Declaration Manufactured by BellBrook Labs.
Shipping and Handling
Shipping DRY ICE
Short Term Storage -20°C
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Documents
Manual Download PDF
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

The Transcreener® HTS Assay platform overcomes the need for time-consuming, one-off assay development for individual members within a group transfer enzyme family by utilizing a single set of assay reagents that detect an invariant product. The generic nature of the Transcreener® HTS Assay platform eliminates delays involved in assay development for new HTS targets, and greatly simplifies compound and inhibitor profiling across multiple target families. Transcreener assays have been validated with major HTS instruments to determine the optimal filters and settings for maximal assay performance. Application notes with all important details are available.

The Transcreener ADP2 assay is available in three fluorescent readouts, Fluorescence polarization (FP), Fluorescence intensity (FI) and Time-resolved Forster-resonance-energy-transfer (TR-FRET), which provide a safe HTS-compatible alternative to cumbersome radioassay methods and are more sensitive and less subject to interference than other detection methods. All readouts use far-red tracers to minimize compound interference and lower false-positive rates.

The Transcreener® ADP2 FI Assay (Prod. No. BBL-3013) is a red, competitive fluorescence intensity (FI) assay based on the detection of ADP and therefore is compatible with any enzyme class that produces ADP, including protein, lipid, and carbohydrate kinases, ATPases, DNA helicases, carboxylases and glutamine synthetase. The Transcreener® ADP2 Assay is a simple one step homogenous detection assay, and is flexible with regard to ATP concentration (0.1 to 100 μM ATP). The assay provides excellent signal at low substrate conversion, with a Z’ = 0.7 at 2.5% ATP conversion using 1 μM ATP.

Product References
  1. Primuline derivatives that mimic RNA to stimulate hepatitis C virus NS3 helicase-catalyzed ATP hydrolysis: N.L. Sweeney, et al.; J. Biol. Chem. 288, 19949 (2013)
  2. A High-Throughput Method for Measuring Drug Residence Time Using the Transcreener ADP Assay: M. Kumar & R.G. Lowery; LSAS Discov. 22, 915 (2017)
  3. A High-Throughput Screening Triage Workflow to Authenticate a Novel Series of PFKFB3 Inhibitors: S.A. St-Gallay, et al.; SLAS Discovery 23, 11 (2018)
  4. Characterization of the Golgi c10orf76-PI4KB complex, and its necessity for Golgi PI4P levels and enterovirus replication: J.A. McPhail, et al.; EMBO Rep. e48441 (2019)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.